Effects of Acleara Needle Insert on Acne
Launched by THERAVANT CORPORATION · Aug 29, 2012
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects \>14 years of age
- • Subject has mild to moderate acne vulgaris on the face, chest or back.
- • Subject has one or more inflammatory acne lesions on face, chest or back.
- • Willingness to participate in the study
- • Informed consent agreement signed by the subject
- • Willingness to follow the treatment schedule and post treatment care requirements
- • Willingness to remain on current acne therapy as directed by the Investigator.
- Exclusion Criteria:
- • Subject has an infection or other dermatologic condition (aside from acne) in the area to be treated
- • Subject is immunosuppressed
- • Subject is unable to comply with treatment or follow-up visits
- • Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
About Theravant Corporation
Theravant Corporation is a biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on clinical research and development, Theravant harnesses cutting-edge science and technology to develop novel treatments aimed at improving patient outcomes. Committed to collaboration and ethical practices, the company engages with healthcare professionals, patients, and stakeholders to ensure that its clinical trials are designed to generate meaningful data and drive forward the next generation of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bellaire, Texas, United States
White Plains, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials